| Stage | JHG | % of rev | CPRX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $690M | 100.00% | $149M | 100.00% | JHG ×4.62 |
| Gross profit | $489M | 70.87% | $135M | 90.31% | CPRX +19.4pp |
| Operating income | $114M | 16.51% | $73M | 49.02% | CPRX +32.5pp |
| Pre-tax income | $136M | 19.70% | $84M | 56.38% | CPRX +36.7pp |
| Net income | $107M | 15.48% | $64M | 42.66% | CPRX +27.2pp |
| Stage | JHG | CPRX | Gap · A − B |
|---|---|---|---|
| Revenue | $690M100.00% | $149M100.00% | JHG ×4.62 |
| Gross profit | 70.87%$489M | 90.31%$135M | CPRX +19.4pp |
| Operating income | 16.51%$114M | 49.02%$73M | CPRX +32.5pp |
| Pre-tax income | 19.70%$136M | 56.38%$84M | CPRX +36.7pp |
| Net income |
| 15.48%$107M |
| 42.66%$64M |
| CPRX +27.2pp |
No disclosed counterparties: JHG, CPRX.